Dekaban Gregory A, Dikeakos Jimmy D
Department of Microbiology and Immunology, Schulich School of Medicine and Dentistry, The University of Western Ontario, Dental Sciences Building, Room 3007J, London, ON, N6A 5C1, Canada.
BioTherapeutics Research Laboratory, Molecular Medicine Research Laboratories, Robarts Research Institute, The University of Western Ontario, Room 2421A, London, ON, N6A 5B7, Canada.
AIDS Res Ther. 2017 Sep 12;14(1):53. doi: 10.1186/s12981-017-0175-6.
The success of many current vaccines relies on a formulation that incorporates an immune activating adjuvant. This will hold true for the design of a successful therapeutic HIV vaccine targeted at controlling reactivated virus following cessation of combined antiretroviral therapy (cART). The HIV accessory protein Nef functions by interfering with HIV antigen presentation through the major histocompatibility complex I (MHC-I) pathway thereby suppressing CD8 cytotoxic T cell (CTL)-mediated killing of HIV infected cells. Thus, this important impediment to HIV vaccine success must be circumvented. This review covers our current knowledge of Nef inhibitors that may serve as immune adjuvants that will specifically restore and enhance CTL-mediated killing of reactivated HIV infected cells as part of an overall vaccine strategy to affect a cure for HIV infection.
许多现有疫苗的成功依赖于包含免疫激活佐剂的配方。对于旨在控制联合抗逆转录病毒疗法（cART）停止后重新激活的病毒的成功治疗性HIV疫苗的设计而言，情况也是如此。HIV辅助蛋白Nef通过干扰主要组织相容性复合体I（MHC-I）途径的HIV抗原呈递发挥作用，从而抑制CD8细胞毒性T细胞（CTL）介导的对HIV感染细胞的杀伤。因此，必须克服这一阻碍HIV疫苗成功的重要障碍。本综述涵盖了我们目前对Nef抑制剂的了解，这些抑制剂可作为免疫佐剂，作为影响治愈HIV感染的整体疫苗策略的一部分，特异性恢复和增强CTL介导的对重新激活的HIV感染细胞的杀伤。
